Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of vestronidase alfa in Japanese patients with mucopolysaccharidosis type VII (Sly disease)
jRCT2051190085Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Mar 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of vestronidase alfa in mucopolysaccharidosis type VII, sponsored by Amicus Therapeutics. Primary endpoint: Adverse events. Started Mar 2020; status: active, not recruiting.
02
Drugs
vestronidase alfa
03
Conditions
mucopolysaccharidosis type VII
Beyond the preview
Go deeper on jRCT2051190085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190085.